Clinical Trials Logo

Clinical Trial Summary

Aim of the study is to evaluate the usefulness of interleukin 33 in the blood plasma in patients with the acute ischemic stroke of the brain in relation to mode of treatment (thrombolysis, thrombectomy, no treatment), risk factors in correlation with other inflammatory state markers (hsCRP, morphology with smear ). Blood is collected on the first and seventh days of stroke.

The purpose is to clarify utility of IL 33 as a biomarker of acute stroke.

Clinical Trial Description

Stroke is the third most frequent cause of death in highly developed countries (after heart disease and cancer), the main cause of disability in adults and the second most frequent cause of dementia syndromes. The annual incidence of stroke in the general population is approximately 0.2%. The risk of stroke increases with age.

Globally 15 million people are affected each year and 5.5 million die every year for this reason (20% in 30 days and up to 40% in a year from getting ill). In Poland, the incidence of stroke is around 175/100,000 in men and 125/100 in women.It is assumed that the cause of sudden cerebral insufficiency is mainly the embolism coming from the newly formed wall clot forming at the site of the atherosclerotic plaque rupture.

In recent years, the role of inflammatory factors is associated with the occurrence of severe atherosclerotic complications such as stroke or heart attack. Cytokines are glycoproteins that are released by activated cells of various tissues. They have a significant impact on the inflammation processes, they control all phases of the immune response. Interleukin is one of the cytokine groups. This study aims to find a relationship between level of IL 33 concentration and the size of the stroke and neurological deficit.

Blood will be collected on the first and seventh days of stroke for examination of Il 33, blood morphology and hsCRP ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03948802
Study type Observational
Source Jan Biziel University Hospital No 2 in Bydgoszcz
Contact Pawel Sokal
Phone 48600954415
Status Recruiting
Start date January 1, 2019
Completion date January 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Not yet recruiting NCT03843008 - Melatonin in Acute Stroke N/A
Recruiting NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders N/A
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT02924168 - Radial Shock Waves for Functional Disability in Stroke N/A
Completed NCT01968122 - Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China N/A
Not yet recruiting NCT01923818 - Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events Phase 2/Phase 3
Suspended NCT01852201 - POSITIVE Stroke Clinical Trial N/A
Completed NCT01983644 - RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study N/A
Completed NCT01949948 - Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke Phase 3
Completed NCT02184936 - Measuring Collaterals With Multi-phase CT Angiography in Patients With Ischemic Stroke N/A
Recruiting NCT01526824 - Lovaza's Effect on Clopidogrel in a Neuro Population Phase 0